Austin isn’t exactly the city you picture when you think about a biotech company pushing iPSC science into Phase 3 territory for women’s health, but that’s exactly where Gameto planted its flag. And now they’ve just landed $44 million in Series C funding led by Overwater Ventures, with Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, and Portfolia stacking in behind them. Add that to a $33M Series B, a $17M Series A, and a $10 million ARPA-H grant, and you’re looking at $127 million total to take one of the most ambitious ideas in reproductive medicine from the lab bench to the delivery room.
Co-founder and CEO Dr. Dina Radenkovic and Co-founder and Chairman Martin Varsavsky aren’t just running a company, they’re running point on a scientific pivot that could make ovarian biology as programmable as software. Fertilo, their iPSC-derived ovarian support cell therapy, is already the first of its kind in late-stage U.S. clinical development. It’s not theory. It’s in pivotal Phase 3 trials at up to 20 sites, from Shady Grove Fertility to Columbia University and across the Prelude Fertility network. Five live births and over 20 pregnancies are already on the board, and in places like Australia, Peru, and Mexico, Fertilo isn’t just cleared, it’s being used.
The technology? Engineered ovarian support cells that recreate the follicular environment outside the body. Translation: they can take the hormone-heavy, two-week grind of egg maturation and condense it into a few days. Less stress on the body, less time on the clock, and a lot more accessibility. And Gameto isn’t stopping there. Under ARPA-H’s women’s health sprint, they’re advancing Ameno, a menopause therapy that doesn’t just throw hormones at the problem but uses cell-based precision to tackle the biology itself. The Deovo platform adds another layer, an AI-powered in vitro organoid system that could turn drug discovery for ovarian aging into a faster, safer, infinitely more scalable game.
Credit where it’s due, this kind of capital doesn’t flow without proof. Regulatory wins in Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay show Gameto can navigate the maze globally. Their GMP facilities in Bee Cave and New York give them the muscle to scale, while a leadership bench including Chief Scientific Officer Christian Kramme, Chief Medical Officer Gus Haddad, and Chief Legal Officer Agustina Imfeld keeps the execution sharp.
This isn’t just about infertility treatments. It’s about owning the biological infrastructure of women’s health for the next century. Gameto’s raising the capital, proving the science, and building the manufacturing to make it happen. The question isn’t whether they can deliver; it’s how fast the rest of the industry can catch up.
